<DOC>
	<DOCNO>NCT02383966</DOCNO>
	<brief_summary>This trial aim assess efficacy safety cetuximab give combination chemotherapy compare chemotherapy alone Chinese subject recurrent and/or metastatic squamous cell carcinoma head neck ( SCCHN ) first-line treatment .</brief_summary>
	<brief_title>Phase III Trial Assess Efficacy Safety Cetuximab Treatment Chinese Subjects With Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis SCCHN Recurrent and/or metastatic SCCHN , suitable localregional treatment Presence least 1 measurable lesion accord RECIST Version 1.1 Signed write informed consent trialrelated activity carry Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Other protocoldefined inclusion criterion could apply Prior systemic chemotherapy , except give part multimodal treatment locally advanced disease , complete within 6 month trial entry Surgery ( exclude prior biopsy diagnosis ) irradiation within 4 week trial entry Previous treatment monoclonal antibody signal transduction inhibitor target epidermal growth factor receptor Nasopharyngeal carcinoma Known central nervous system metastasis and/or leptomeningeal disease Medical psychological condition would permit subject complete trial sign inform consent Legal incapacity limit legal capacity Other protocoldefined exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>